Eris Lifesciences Acquires Probiotics Business from Velbiom for ₹50 Crore
Eris Lifesciences acquired Velbiom Probiotics' branded probiotic products for ₹50 crore on a slump sale basis. The acquired business had revenues of ₹16.02 crore in 9M FY26. The deal was approved by the board on March 20, 2026.
The acquisition is of a specific business vertical and involves a consideration of ₹50 crore, which is a significant but not transformative amount for a company of Eris Lifesciences' scale. It will likely have a medium-term impact on its product portfolio and market presence in the probiotics segment.
The acquisition of a business with consistent revenue generation is a positive development for Eris Lifesciences, indicating strategic expansion.
Eris Lifesciences Limited announced the execution of a Business Transfer Agreement (BTA) with Velbiom Probiotics Private Limited for the acquisition of their branded probiotic products on a slump sale basis. The agreement was approved and duly executed on March 20, 2026.
The acquired portfolio from Velbiom, a science-driven bio-therapeutics company, includes various formulations of prebiotics and probiotics targeting metabolic health, gut wellness, and women’s health. The acquired business reported revenues of ₹16.02 crore for the 9-month period of FY26, ₹19.64 crore for FY25, and ₹17.56 crore for FY24.
The total consideration for this acquisition is ₹50 crore. The Board of Directors meeting, which commenced at 12:45 PM and concluded at 3:15 PM on March 20, 2026, also approved this transaction. This is not a related party transaction and does not require an arms-length assessment.
What to do with a filing like this
Eris Lifesciences Limited filed this with the NSE as a statutory disclosure, categorised under acquisition. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Eris Lifesciences Limited. Read the original for the full detail.